No Photo Available

Last Update

2017-02-23T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong William Kerns?

Dr. William D. Kerns

Chief Executive Officer

Accellient Partners LLC

Direct Phone: (978) ***-****       

Email: b***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Accellient Partners LLC

1000 Winter Street, Suite 2000

Waltham, Massachusetts 02451

United States

Company Description

Accellient was founded by a team of seasoned life science experts with years of pharma/biotech, CRO and consulting experience. The Accellient Partners' team brings a unique combination of knowledge and innovative thinking to product development across all ... more

Find other employees at this company (11)

Background Information

Employment History

Vice President, Drug Development

Can-Fite BioPharma Ltd

Affiliations

Scientific Advisory Board Member
Sphaera Pharma

Board Member
Synchroneuron Inc

Treasurer
NTSRI

Scientific Advisory Board Member
Taiwan Liposome Company

Advisor
Critical Path Institute

Board Member
Calvert Holdings , Inc.

Scientific Advisory Board
Ricerca Biosciences LLC

Education

American College of Veterinary Pathologists

DVM

DVM

The Ohio State University

MS

MS

Ohio State University

undergraduate degree

Wilmington College

Web References (69 Total References)


Scientific Advisory Board

www.sphaerapharma.com [cached]

William D. Kerns, DVM, MS, DACVP Dr. William Kerns, has over 25 years of experience in Drug Discovery and Development. In addition to his role at Sphaera Pharma, he is the CEO of Accellient Partners LLC. Read more


Accellient Partners | Management Team

www.accellient.com [cached]

Bill Kerns, DVM, MS, DACVP Partner Chief Executive Officer

Regulatory & Drug Development


Scientific Advisory Board

www.sphaerapharma.com [cached]

William D. Kerns, DVM, MS, DACVP


Synchroneuron | Board of Directors

www.synchroneuron.com [cached]

William D Kerns DVM, MS Interim CEO

Dr. Kerns is an entrepreneur and co-founder of Synchroneuron Inc. He completed his medical training in Veterinary Medicine and graduate work in Pharmacology and Pathology at The Ohio State University. In his graduate program, he studied molecular mechanisms of cardiac hypertrophy. In 1980, he successfully completed examination by the American College of Veterinary Pathologists.
Dr. Kerns has 30 years of experience in pharmaceutical research and development, having held senior executive positions in preclinical development at SmithKlineFrench, SmithKlineBeecham (both now part of GlaxoSmithKline), and Eisai during his pharmaceutical career. He is recognized as an expert in drug development and safety assessment with a focus on mechanisms of drug-induced cardiovascular toxicity. He has authored or co-authored over 100 articles and has co-edited a book on cardiovascular toxicology. He has been actively involved in the SOT, STP and ACVP and he has co-chaired an FDA expert committee on biomarkers of drug-induced vascular injury. .
Dr. Kerns has participated in the successful management and activation of over 200 INDs and 15 NDAs during his career. Currently he oversees the submission of 3-4 INDs each year across multiple divisions at FDA.
Dr. Kerns is also a co-founder and the CEO of Accellient Partners, LLC, a drug development consultancy.


Synchroneuron | Management Team

www.synchroneuron.com [cached]

William D Kerns DVM, MS, DACVP Interim CEO

Dr. Kerns is an entrepreneur and co-founder of Synchroneuron Inc. He completed his medical training in Veterinary Medicine and graduate work in Pharmacology and Pathology at The Ohio State University. In his graduate program, he studied molecular mechanisms of cardiac hypertrophy. In 1980, he successfully completed examination by the American College of Veterinary Pathologists.
Dr. Kerns has 30 years of experience in pharmaceutical research and development, having held senior executive positions in preclinical development at SmithKlineFrench, SmithKlineBeecham, and Eisai during his pharmaceutical career. He is recognized as an expert in drug development and safety assessment and an expert on mechanisms of drug-induced cardiovascular toxicity. He has authored or co-authored over 100 articles and has co-edited a book on cardiovascular toxicology. He has been actively involved in the SOT, STP and ACVP and he has co-chaired an FDA expert committee on biomarkers of drug-induced vascular injury. .
Dr. Kerns has participated in the successful management and activation of over 200 INDs and 15 NDAs during his career. Currently he oversees the submission of 3-4 INDs each year across multiple divisions at FDA. .
Dr. Kerns is also a co-founder and the CEO of Accellient Partners, LLC, a drug development consultancy in Waltham, MA.

Similar Profiles

Other People with this Name

Other people with the name Kerns

Desiree Kerns Hukmani
Iggesund Paperboard AB

Kaitlin Kerns
Team One

Brandon Kerns
Tipton Group Inc

Emily Kerns
Thompson Technologies Inc

Shannon Kerns
Bumble Bee Seafoods Inc.

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory